First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® . With Illuccix now available nationwide in Canada through Telix's partner Isologic Innovative Radiopharmaceuticals (Isologic), INITIO Medical Group in Burnaby, BC...
HanX Biopharmaceuticals announces HX009 IND approval from FDA
WUHAN, China, May 22, 2023 /PRNewswire/ -- Hanx Biopharmaceuticals, Inc. (HanxBio), announced that the company has received Investigational New Drug (IND) approval to start clinical trial of the potentially first-in-class recombinant anti-CD47/PD-1 bispecific antibody (BsAb), HX009, in Patients with relapsed/refractory Lymphoma. This is a Phase IB/II clinical study to be conducted in the United States to evaluate HX009 in...
upGrad enters Pacific Region to set up the largest Institute of Medical Sciences
ATLANTA, June 13, 2023 /PRNewswire/ -- upGrad, Asia's largest integrated learning skilling and workforce development company announced the setting up of upGrad Institute of Medical Sciences (UIMS), a fully-offline campus in the Republic of Vanuatu to attract and train global talent with modern-day clinical competencies and build the next crop of skilled...
Holmusk and Streamline Healthcare Solutions Announce Strategic Partnership To Bring Behavioral Health Predictive Analytics Tool to US Market
Initial phase will bring MaST, Holmusk's tool to help healthcare professionals better prioritize and manage behavioral health caseloads, to Mental Health Partners in Colorado NEW YORK, June 22, 2023 /PRNewswire/ -- Holmusk, a leading global behavioral health real-world evidence company, announced today that it is joining forces with one of its strategic partners, Streamline Healthcare Solutions, to enhance care delivery using...
MEDICAL IP Received US FDA 510(k) Clearance for DeepCatch, AI Software for Whole-Body Composition CT Quantification
The world's first FDA cleared solution that automatically analyzes bone, muscle, visceral fat, subcutaneous fat, internal organ, and central nervous system in whole-body CT Validation using multi-site and multi-racial CT data in the US… "We will create a new global standard for body composition analysis" SEOUL, South Korea and SILVER SPRING, Md., June 26, 2023...
SIFI TO PRESENT NEW SCIENTIFIC DATA DURING THE 41ST CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS
CATANIA, Italy, Sept. 8, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company, is pleased to announce the presentation of new scientific data on its products during the upcoming Congress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from September 8-12 in Vienna. "SIFI is committed to supporting continuous scientific exchange to help ophthalmologists get...
Noted National TCM Master Inaugurates New Infinitus Research and Technology Laboratory
GUANGZHOU, China, Oct. 27, 2023 /PRNewswire/ – The unveiling ceremony for the joint laboratory, a collaboration between Infinitus and the Shandong University of Traditional Chinese Medicine dedicated to Xuezhuo-turbid blood research, took place at Infinitus Plaza. The event drew attention from over 100,000 participants, both on-site and virtually. Joint Laboratory of Infinitus-Shandong University of Traditional Chinese Medicine Blood...
PYC’S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
PYC has developed a new drug candidate for the >5 million people worldwide with Polycystic Kidney Disease (PKD) This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD PKD is a life-changing disease affecting 1 in every 1,000 people Half of the patient population with PKD will require...
The PolG Foundation awards over $3.5M in academic grants to pioneer POLG research
NEW YORK and PARIS, Nov. 15, 2023 /PRNewswire/ --The PolG Foundation is a nascent foundation established in 2022 by a PolG family, with the mission to support and accelerate research to find effective treatments and a cure for PolG mitochondrial disorders. To view the Multimedia News Release, please click: https://www.multivu.com/players/English/9224051-polg-foundation-awards-academic-grants-pioneer-polg-research/ With both a dedicated and experienced Board of...
Supplemental New Drug Application for Akeso’s Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab (开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XELOX) for first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. This will be the...
